The Cigna Group (CI) Stock Price & Analysis

The Cigna Group (CI) closed at USD 315.88 on Thursday, October 22, 2026, up 3.78% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 304.37; the Oct 22, 2026 session ranged USD 304.68–316.27 on volume of 1,575,611 shares. Market capitalization is $83.47B, with a 52-week range of USD 239.51–316.27 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CI.md

Key facts (CI)

• Last four reported quarters (through Jun 30, 2026): revenue $282B, net income $6.23B (2.2% margin) (SEC filings).
• Valuation: P/E 13.4x (avg 17.5x at the last 3 fiscal year-ends), EV/EBITDA 8.5x, net debt $24.6B.
• 7 of 80 tracked superinvestors hold CI (13F, Q2 2026): 0 new, 4 added, 1 reduced, 2 unchanged.
• Insider open-market sales, last ~7 months: 5 Form 4 filings, $65.7M; 1 not under a Rule 10b5-1 plan ($268K); 1 by opportunistic insiders (0 outside 10b5-1 plans), 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.08 on a 1–5 scale) (24 analysts), mean target USD 342.29 (range 288–400).
• Total return with dividends: 1Y +5.9% vs S&P 500 +14.9%; 5Y +60.2% vs S&P 500 +80.3%.
• Next earnings: 2026-11-05, EPS estimate USD 7.51, revenue estimate $72.4B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CI)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CI)

P/E 13.4x · P/S 0.3x · EV/EBITDA 8.5x · EV/Sales 0.4x · P/B 2.0x · Earnings yield 7.46% · Dividend yield (paid, TTM) 1.95% · Buyback yield (TTM) 1.53% · Net debt $24.6B · EV $108B

P/E at fiscal year-ends: Dec 2025 12.4x, Dec 2024 22.8x, Dec 2023 17.2x.

Superinvestors (SEC 13F-HR, Q2 2026) (CI)

7 of 80 tracked investors hold CI. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (CI)

4 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CI)

Consensus Buy (mean 2.08 on a 1–5 scale), 24 analysts; mean target USD 342.29 (low 288, high 400).

Rating changes, last 120 days:

Total return (dividends reinvested) (CI)

CI revenue by business segment (quarter ended Jun 30, 2026)

CI revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

CI suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

CI customer concentration

In the period ended Dec 31, 2025, a single direct customer accounted for 19% of revenue, per the company's 10-K filed Feb 26, 2026. The company does not name it.

CI analyst estimates and revisions

CI options: expected move

Options price a move of about ±7.0% (±$22.00) by Nov 6, 2026, which includes earnings on Nov 5, 2026; the earnings reaction alone is priced at about ±5.1%. Over the last 8 reports the stock moved ±6.5% on average.

30-day implied volatility 34.5% vs 26.4% realized over the last 30 trading days. Put/call ratio (volume) 0.35. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:23 UTC)

Technical Analysis (CI)

Nexqual's technical model rates CI "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.

Analyst Ratings (CI)

Wall Street analysts rate CI "Buy" based on 24 analysts, with a mean price target of USD 342.29 (range USD 288–400), per Nexqual as of October 23, 2026 at 09:23 UTC.

Earnings (CI)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financials & Fundamentals (CI)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Financial Health Score (CI)

Nexqual rates The Cigna Group's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.

Ownership (CI)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

Leadership (CI)

The Cigna Group is led by Brian Case Evanko C.F.A., President, CEO & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.

Major Backers & Investors (CI)

Notable institutional backers of The Cigna Group include Dodge & Cox Inc., Massachusetts Financial Services Co., Sanders Capital, LLC, according to Nexqual as of October 23, 2026 at 09:23 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:23 UTC.

From The Cigna Group's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our formulary management services support clients in establishing formularies that assist customers and physicians in choosing clinically appropriate, cost-effective drugs and prioritize access, safety and affordability. ▪We administer specific formularies for our clients, including standard formularies developed by Express Scripts® Pharmacy Benefit Services ("Express Scripts") and custom formularies in which we play a more limited role.
• Health System Services includes CuraScript SD by Evernorth®, which is a specialty distributor of pharmaceuticals and medical supplies (including injectable and infusible pharmaceuticals and medications to treat specialty and rare or orphan diseases) directly to health care providers, including clinics and hospitals in the United States for office or clinic administration.
• We use these patents to protect our proprietary technological advances and to differentiate ourselves in the market.
• Our ability to deliver this broad array of health care services on either a standalone or combined basis between its two operating segments enables us to drive incremental growth.

Partnerships

• Through our clinical programs and partnership with EviCore, we guide care to the most appropriate settings, reducing unnecessary costs while preserving quality and service, and offer virtual care options, including MD Live, to improve convenience and access.

Legal & Regulatory Risks (Item 1A, quoted)

• Our business is subject to substantial government regulation, and new laws or regulations or changes in existing laws or regulations could have a material adverse effect on our business, results of operations, financial condition and liquidity.
• Our use of artificial intelligence and machine learning present regulatory and legal challenges that could negatively affect our business and our reputation.
• The reserves we hold for expected medical claims are based on estimates that involve an extensive degree of judgment and are inherently variable. If actual claims exceed our estimates, our operating results could be materially adversely affected, and our ability to take timely corrective actions to contain future costs may be limited.
• Legal, Regulatory and Public Policy Risks Arising from Our Business

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt